FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 384 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Pembrolizumab for Advanced Oesophageal or Gastro-Oesophageal Carcinoma March 30, 2021 Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... March 17, 2025 FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC September 18, 2024 Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit In? October 11, 2024 Load more HOT NEWS A new approach to cancer immunotherapy Colonoscopy after Positive FIT Test Cuts Risk of Colorectal Cancer Death In Memory of Håkan Mellstedt: Former ESMO President Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After...
